• 12/06/2010

     PAION reports positive preclinical results of its substance Solulin in the indication haemophilia

  • 11/22/2010

    PAION reports positive results of its short acting anaesthetic/sedative Remimazolam (CNS 7056) in a Phase IIb study

  • 11/10/2010

    PAION AG reports results for the first nine months 2010

  • 10/15/2010

    PAION expands Desmoteplase agreement with Lundbeck

  • 09/27/2010

    PAION completes Phase IIb study with short-acting anesthetic/sedative Remimazolam (CNS 7056)

  • 08/11/2010

    PAION AG reports results for the first half-year 2010

  • 08/02/2010

    PAION's Phase IIb study with its anaesthetic/sedative Remimazolam (CNS 7056) ahead of schedule

  • 05/28/2010

    PAION starts Phase IIb study with its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy

  • 05/11/2010

    PAION AG reports results for the first quarter 2010

  • 05/10/2010

    PAION AG enters into an equity facility agreement for EUR 15 million

  • 05/10/2010

    Start of Japanese Phase I with CNS 7056 triggered first milestone of one million USD for PAION from Ono Pharmaceutical

  • 04/27/2010

    PAION reaches agreement with FDA on Phase IIb study design for its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy

  • 04/21/2010

    Filing of IND application for GGF2 in heart failure by PAION's partner Acorda Therapeutics triggers first milestone payments

  • 03/16/2010

    PAION's partner Lundbeck initiates Japanese Clinical Phase II Trial with Desmoteplase in ischaemic stroke

  • 03/16/2010

    PAION AG reports results for the fiscal year 2009

  • 02/25/2010

    PAION's partner Lundbeck presented data from a post-hoc analysis using Desmoteplase in ischaemic stroke

  • 02/04/2010

    PAION announces initiation of clinical development activities with short-acting anaesthetic/sedative CNS 7056 (ONO's Development code: ONO-2745) by its Partner ONO Pharmaceutical in Japan